Hakutulokset - Annemarie N. Lekkerkerker

A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers Tekijä Nicholas S. Jones, Smita Kshirsagar, Vishnu Mohanan, Vidya Ramakrishnan, Flavia Di Nucci, Ling Ma, Jialin Mao, Hao Ding, Sha Klabunde, Domagoj Vucic, Lin Pan, Annemarie N. Lekkerkerker, Yuan Chen, Michael E. Rothenberg

Connect to this object online.